CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 122 enrolled
Drug / intervention
Crizotinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00939770
NCT00939770Phase 2Completed
CompareCT.gov

A Phase 1/2 Study of Crizotinib, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Children's Oncology Group·interventional·Posted Jul 15, 2009·Updated Jun 9, 2020

In Brief

A Phase 2 clinical trial evaluating Crizotinib, Laboratory Biomarker Analysis, and 2 other interventions for Recurrent Childhood Anaplastic Large Cell Lymphoma and 5 related conditions. Completed, enrolled 122 participants across 28 sites in 2 countries.

Detailed Summary

This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma
CountriesCanada, United States
CollaboratorsNational Cancer Institute (NCI), Pfizer

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 15, 2009
Enrollment StartSep 21, 2009
Primary CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 17.0 years ago

Interventions

Crizotinibdrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Pharmacological Studyother

Correlative studies

Questionnaire Administrationother

Ancillary studies